This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD's (BDX) First Self-Collection HPV Screening Assay Gets CE Mark
by Zacks Equity Research
BD's (BDX) industry-first CE marked self-collection claim for HPV screening enables greater access to testing for women.
6 GARP Stocks for a Winning Portfolio
by Shilpa Mete
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
HCA Healthcare (HCA) to Divest Hospital for Better Liquidity
by Zacks Equity Research
HCA Healthcare (HCA) to sell Redmond Regional Medical Center, GA to AdventHealth for boosting financial solvency.
National Vision (EYE) Q1 Earnings Top Estimates, View Up
by Zacks Equity Research
According to National Vision (EYE), increased demand for low-cost eye exams, glasses and contact lenses boosts first-quarter performance.
PRA Health's (PRAH) New Solution to Speed Up Drug Development
by Zacks Equity Research
PRA Health's (PRAH) tokenization solution can help in the generation of enhanced evidence for drug development through Synoma.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
Haemonetics (HAE) Q4 Earnings Lag Estimates, Gross Margin Dips
by Zacks Equity Research
Haemonetics' (HAE) fourth-quarter fiscal 2021 revenues declined 5.6% year over year due to the pandemic.
The Zacks Analyst Blog Highlights: Centene Corp, Molina Healthcare, UnitedHealthGroup, Cigna Corp and HCA Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Centene Corp, Molina Healthcare, UnitedHealthGroup, Cigna Corp and HCA Healthcare
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Investors' confidence is high in Nevro (NVRO) stock, courtesy of its solid prospects.
Here's Why You Should Retain Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System. However, rise in production costs is a woe.
Glaukos (GKOS) Loses 14.3% Despite Narrower Loss in Q1
by Zacks Equity Research
Despite reporting first-quarter loss, Glaukos' (GKOS) results reflect rise in revenues.
Fresenius Medical (FMS) Gains 1.1% Since Q1 Earnings Beat
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from organic growth in Health Care Products segment, and performance in Asia Pacific.
Cardiovascular Systems (CSII) Q3 Loss Widens, Gross Margin Dips
by Zacks Equity Research
Increase in vaccinations and simultaneous decrease in COVID-19 hospitalizations in February and March result in improved procedure volumes for Cardiovascular Systems (CSII) in Q3.
Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Intersect ENT (XENT) first-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
LHC Group (LHCG) Loses 1.1% In Spite of Q1 Earnings Beat
by Zacks Equity Research
LHC Group's (LHCG) first-quarter results benefit from organic growth in hospice admissions.
MEDNAX's (MD) Q1 Earnings Surpass Estimates, Decline Y/Y
by Zacks Equity Research
MEDNAX's (MD) Q1 results reflect lower costs. However, the same is partly offset by softer revenues.
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the first quarter.
What's in Store for Intersect ENT's (XENT) Q1 Earnings?
by Zacks Equity Research
PROPEL and SINUVA are expected to have contributed to Intersect ENT's (XENT) first-quarter revenues.
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gains from segmental strength in the first quarter.
Nevro (NVRO) Stock Slips 2.9% Despite Narrower Loss in Q1
by Zacks Equity Research
Nevro's (NVRO) international revenues rise on a year-over-year basis in Q1.
Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.
Phibro (PAHC) Q3 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Phibro's (PAHC) fiscal third-quarter revenues improved year over year on growth in Performance Products and Mineral Nutrition segments.
Select Medical (SEM) Beats on Q1 Earnings, Hikes '21 EPS View
by Zacks Equity Research
Select Medical's (SEM) first-quarter results indicate uptick in revenues stemming from solid segmental performances except Outpatient Rehabilitation, partly offset by higher costs.
McKesson (MCK) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses revenue growth in each of its segments in the first quarter.